Slingshot Insights | Sprb Overview

SPRB Overview

Upcoming Projects (SPRB)

Examining the Breakthrough Therapy Designation of Tralesinidase Alfa (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) from Spruce Biosciences
Ticker: SPRB
Execute By: Oct 21, 2026

Executed Projects (SPRB)

Comparing Neurocrine Biosciences pediatric study results of Crinecerfont in Children and Adolescents with Spruce Biosciences Tildacerfont CAHptain-205 study and dose finding presentation at the Pediatric Endocrine Society (PES) 2024
Tickers: SPRB, NBIX
Executed On: Jun 12, 2024 at 05:00 PM EDT
Discussing CAH (Congenital Adrenal Hyperplasia) and therapies in development, including crinecerfont and tildacerfont
Tickers: SPRB, NBIX
Executed On: Feb 13, 2024 at 04:00 PM EST
A Second Take: Digging into the Phase 2 Data on Spruce Bio's tildacerfont in treating Congenital Adrenal Hyperplasia (CAH)
Ticker: SPRB
Executed On: Mar 13, 2023 at 12:30 PM EDT
A Third View - Digging into the Phase 2 Data on Spruce Bio's tildacerfont in treating Congenital Adrenal Hyperplasia (CAH)
Ticker: SPRB
Executed On: Mar 13, 2023 at 12:00 PM EDT
Digging into the Phase 2 Data on Spruce Bio's tildacerfont in treating Congenital Adrenal Hyperplasia (CAH)
Ticker: SPRB
Executed On: Feb 24, 2023 at 06:00 PM EST

Upcoming & Overdue Catalysts (SPRB)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (SPRB)

Spruce Biosciences (SPRB) to announce Phase 1 and 2 Data of Tildacerfont in Classic Congenital Adrenal Hyperplasia at ENDO March 20, 2021 at 11:00am EST
Ticker: SPRB
Occurred on: Mar 20, 2021

Strategic Initiatives (SPRB)

Don’t see a strategic initiative related to the company you care about? Create your own!